Please assess the completion status of the following clinical trial:

Trial Title: Tofacitinib Registry of Patients With Ulcerative Colitis in Germany

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with moderate to severe Ulcerative Colitis aged 18-80 years at enrollment~* Written informed consent is given~Exclusion Criteria:~* Malignant disease in history (except for non-melanoma skin cancer)~* Any contraindication according to the SmPC of the respective medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: None

Study Arms:
- Group 1 (Type: None): UC-patients (age at enrollment: 18-80 years) receiving a newly introduced Tofacitinib therapy (n=360). Previous treatment(s) with biologics or immunosuppressants is (are) permitted. About 20-30% of the Tofacitinib patients will biologic-naiv.
- Group 2 (Type: None): UC-patients (age at enrollment: 18-80 years) receiving a newly introduced biologics therapy (n=120). Previous treatment(s) with biologics or immunosuppressants is (are) allowed.

Based on this trial design, predict the completion outcome and termination type (if applicable).